Eli Lilly And Company (LLY) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Study IIBD is a new Eli Lilly master trial that will test several drugs in adults with moderate to severe ulcerative colitis or Crohn’s disease. The official goal is to run a set of phase 2 studies under one framework to see how well these treatments work and how safe they are over at least 62 weeks.
The main drugs are mirikizumab, given first by IV and then by under‑the‑skin shots, and an oral drug called LY4395089 that is tested together with mirikizumab. Both aim to calm gut inflammation, reduce symptoms, and help patients stay in remission over time.
The study is interventional and randomized, which means participants are assigned by chance to different treatment groups. It uses a parallel design with no blinding, and the core purpose is to test treatment effects rather than to observe patients in usual care.
The trial was first submitted on 16 Mar 2026, marking the formal start of the setup phase. The latest update on 16 Mar 2026 confirms the status as not yet recruiting, with primary and final completion dates still pending but likely several years out given the 62‑week treatment window.
For investors, this master protocol signals that Lilly is committing more capital to its inflammatory bowel disease pipeline on top of mirikizumab. Positive phase 2 signals could strengthen the case for LLY’s immunology franchise and raise long‑term revenue expectations, while putting pressure on rivals in IBD drugs such as AbbVie and Johnson & Johnson.
The study is not yet enrolling, but the protocol has been recently updated, and more details will be available over time on the ClinicalTrials portal.
To learn more about LLY’s potential, visit the Eli Lilly And Company drug pipeline page.